RTX-321 is an investigational cellular therapy that aims to selectively target HPV 16-associated cancers and potentially induce an immune response against the cancer.
RTX-321 is an investigational cellular therapy that is being evaluated in a Phase 1 clinical trial for the treatment of patients with HPV 16-associated cancers, including cervical cancer, anal cancer and head and neck cancer (including nasal cavity cancer, oral cancer, laryngeal cancer, hypopharyngeal cancer, nasopharyngeal cancer, and oropharyngeal cancer). RTX-321 is engineered to express cancer-fighting molecules and specific proteins, known as antigens, on the cell’s surface. These antigens that are bound to the cell surface may selectively instruct only the cells of the immune system with the ability to potentially recognize and attack the tumor.
Learn more about the RTX-321 Clinical Trial